Evidence map›Paper›PMID 37268635›Full record

ArticleNature communications2023

NOTCH4

Bin Zhang, Shaowei Dong, Jian Wang, Tuxiong Huang, Pan Zhao, Jing Xu, Dongcheng Liu, Li Fu, Lingwei Wang, Guangsuo Wang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Bin Zhang *Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, PR China.ORCID 0000-0002-9264-8554
Shaowei Dong *Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, Guangdong, PR China.
Jian Wang *Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, PR China.
Tuxiong Huang *Department of Pharmacology and International Cancer Center, Shenzhen University Medical School, Shenzhen, Guangdong, PR China.
Pan ZhaoDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, PR China.
Jing XuDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, PR China.
Dongcheng LiuDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, PR China.
Li FuDepartment of Pharmacology and International Cancer Center, Shenzhen University Medical School, Shenzhen, Guangdong, PR China.ORCID 0000-0003-2643-6278
Lingwei WangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, PR China.
Guangsuo WangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, PR China.
Chang ZouDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, PR China. zouchang@cuhk.edu.cn.ORCID 0009-0007-5992-0257
Southern University of Science and Technology · CNShenzhen University Health Science Center · CNShenzhen Children's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI) remains one of the major challenges in lung adenocarcinoma (LUAD) therapy. Here, we find an increased frequency of the L12_16 amino acid deletion mutation in the signal peptide region of NOTCH4 (NOTCH4

Indexed as

Adenocarcinoma of LungLung NeoplasmsCell Line, TumorDown-RegulationDrug Resistance, NeoplasmErbB ReceptorsHumansMutationProtein Kinase InhibitorsReceptor, Notch4Transcription Factor HES-1EGFR protein, humanErbB ReceptorsHES1 protein, humanNOTCH4 protein, humanProtein Kinase InhibitorsReceptor, Notch4Transcription Factor HES-1

Identifiers

PMID37268635
PMCPMC10238419
OpenAlexW4379197386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.